Head to Head Analysis: Imprimis Pharmaceuticals (IMMY) & Its Rivals

Imprimis Pharmaceuticals (NASDAQ: IMMY) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Imprimis Pharmaceuticals to related businesses based on the strength of its dividends, analyst recommendations, valuation, earnings, institutional ownership, profitability and risk.

Insider and Institutional Ownership

12.6% of Imprimis Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are held by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Imprimis Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imprimis Pharmaceuticals 0 0 1 0 3.00
Imprimis Pharmaceuticals Competitors 1133 3423 11925 240 2.67

Imprimis Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 170.27%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.63%. Given Imprimis Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Imprimis Pharmaceuticals is more favorable than its competitors.

Volatility & Risk

Imprimis Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Imprimis Pharmaceuticals’ competitors have a beta of 6.62, suggesting that their average share price is 562% more volatile than the S&P 500.

Valuation and Earnings

This table compares Imprimis Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Imprimis Pharmaceuticals $19.94 million -$19.08 million -2.01
Imprimis Pharmaceuticals Competitors $290.27 million $35.99 million 57.36

Imprimis Pharmaceuticals’ competitors have higher revenue and earnings than Imprimis Pharmaceuticals. Imprimis Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Imprimis Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Imprimis Pharmaceuticals -60.71% -264.98% -57.30%
Imprimis Pharmaceuticals Competitors -5,441.68% -162.70% -35.92%


Imprimis Pharmaceuticals competitors beat Imprimis Pharmaceuticals on 9 of the 13 factors compared.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply